Meridian Wellness Systems LLC · myoguard.health
Observational Research
Infrastructure
A longitudinal observational registry for physician-led data collection at the intersection of GLP-1 receptor agonist therapy and skeletal muscle preservation. Designed to support prospective evaluation of the Sarcopenia Risk Index (SRI) framework.
Observational Registry
Physician-Led Longitudinal Data Collection
The MyoGuard Protocol observational registry is an infrastructure for collecting de-identified cohort data from physician-led SRI assessments across real-world clinical settings. Physicians who prescribe GLP-1 receptor agonists may attribute patients to their registry cohort through the referral architecture.
Each assessment captures sarcopenia risk indicators at a defined point in time. Longitudinal tracking enables trajectory analysis across a patient's GLP-1 treatment course — from initiation through dose escalation and maintenance phases.
Evidence Context
What the Literature Identifies as Unresolved
The following reflects gaps identified in the published literature. These are not claims that MyoGuard Protocol has resolved them.
Muscle mass preservation in GLP-1 therapy
Published data on GLP-1 receptor agonist therapies — including semaglutide and tirzepatide — indicate that a proportion of total weight loss derives from lean mass. The clinical significance of this lean mass attrition over multi-year treatment courses remains incompletely characterised in longitudinal observational studies.
Sarcopenia risk stratification tooling
Standardised, scalable assessment instruments for sarcopenia risk identification in GLP-1-treated outpatient populations are not yet widely deployed. Most published studies rely on DXA or BIA in specialist settings, rather than accessible risk-stratification proxies suitable for integration into primary care clinical workflows.
Protein adequacy in medically supervised weight management
Dietary protein intake monitoring in patients undergoing medically supervised GLP-1 therapy is inconsistent across clinical practice. Observational data linking protein adequacy targets to lean mass preservation outcomes in this population remains sparse.
Infrastructure Architecture
Three-Layer Data Separation
Clinical CDS, observational research infrastructure, and de-identified export operate as distinct architectural layers. PHI never crosses the research boundary.
De-identification Governance
A thirteen-field PHI exclusion set governs all research exports. The sole patient identifier in export data is a pseudonymous research participant ID.
Consent Infrastructure
Patient consent is versioned and auditable. Patients may withdraw at any point; withdrawal triggers data suppression in all future cohort exports.
Clinical Positioning
The MyoGuard Protocol is classified as Physician-led Clinical Decision Support (CDS). All outputs are intended to augment physician clinical judgement — not to replace it.
The Sarcopenia Risk Index (SRI) is an expert-consensus framework. It is not currently a validated clinical instrument. The SRI framework is designed to support prospective evaluation through this observational infrastructure.
A provisional patent application is pending. All intellectual property is held by Meridian Wellness Systems LLC.
Physician Participation
An Invitation to Clinical Colleagues
Physicians who prescribe GLP-1 receptor agonists and wish to contribute to this longitudinal observational registry are invited to explore physician participation. Participating physicians retain attribution within their cohort and receive access to aggregated de-identified findings as the registry matures.
Ethics & Governance
Consent-first design
Patient enrolment in the observational registry requires explicit informed consent. Consent records are versioned and stored independently of clinical CDS records.
Data minimisation
Only the data elements necessary for observational analysis are captured in the research layer. PHI fields are excluded by design from all research exports.
Patient withdrawal rights
Patients may withdraw from the registry at any time. Withdrawal triggers immediate data suppression across all future cohort analyses.
Physician oversight requirement
The registry is designed for physician-attributed data collection. Patient participation is routed through a verified physician relationship.
Classification: Physician-led Clinical Decision Support (CDS). All outputs from the MyoGuard Protocol are intended to support physician clinical judgement and do not constitute medical advice. The Sarcopenia Risk Index (SRI) is an expert-consensus framework and is not currently a validated clinical instrument. The SRI framework is designed to support prospective evaluation through this observational infrastructure. A provisional patent application is pending. All intellectual property is held by Meridian Wellness Systems LLC, Wyoming, USA. MyoGuard Protocol is a trading name of Meridian Wellness Systems LLC.